Suggested remit: To appraise the clinical and cost effectiveness of obinutuzumab within its marketing authorisation for treating serologically active extra renal lupus.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6670
Provisional Schedule
- Committee meeting:
- 02 December 2026
- Expected publication:
- 13 May 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- Roche (obinutuzumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action on Pain
- AOFAC Foundation
- Anthony Nolan
- Arthritis Action
- Arthritis & Musculoskeletal Alliance
- Arthritis UK
- British Sjögren’s Syndrome Association
- Changing Faces
- Genetic Alliance UK
- Gene People
- Hibbs Lupus Trust
- Kidney Care UK
- Kidney Research UK
- Let’s Face It
- Lupus Trust
- Lupus UK
- National Kidney Federation
- National Rheumatoid Arthritis Society
- Pain Concern
- Pain UK
- Polycystic Kidney Disease Charity
- Scleroderma and Raynaud’s UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Thrombosis UK
- Professional groups
- Association of Renal Industries
- Association of Renal Technologists
- British Association for Surgery of the Knee
- British Association of Dermatologists
- British Association of Urological Nurses
- British Association of Urological Surgeons
- British Dermatological Nursing Group
- British Geriatrics Society
- British Isles Lupus Assessment Group
- British Myology Society
- British Orthopaedic Association
- British Orthopaedic Foot and Ankle Society
- British Society for Allergy and Clinical Immunology
- British Society for Children’s Orthopaedic Surgery
- British Society for Haematology
- BSI Clinical Immunology Professional Network (BSI-CIPN)
- British Society for Rheumatology
- British Society of Haemostasis and Thrombosis
- British Society of Physical and Rehabilitation Medicine
- British Thoracic Society
- Clinical Leaders of Thrombosis
- Physiotherapy Pain Association
- Primary Care Dermatology Society
- Primary Care Rheumatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for DGH Nephrologists
- Society for Endocrinology
- Society for Vascular Technology
- Society for Vascular Ultrasound
- Society of Vascular Nurses
- UK Clinical Pharmacy Association
- UK Kidney Association
- UK Renal Pharmacy Group
- Urology Foundation
- Vascular Society of Great Britain and Ireland
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Baxter Healthcare (cyclophosphamide)
- Blackrock Pharmaceuticals (hydroxychloroquine)
- Celltrion Healthcare (rituximab)
- Cipla (methotrexate)
- Dr Reddy's Laboratories (rituximab)
- Esteve Pharmaceuticals (methotrexate)
- GlaxoSmithKline (belimumab)
- Hospira UK (methotrexate)
- Ipca Laboratories (hydroxychloroquine)
- Medac Pharma (methotrexate)
- Morningside Healthcare (methotrexate)
- Nova Laboratories (azathioprine)
- Organon Pharma (methotrexate)
- Pfizer (rituximab)
- Rosemont Pharmaceuticals (methotrexate, mycophenolate mofetil)
- Sandoz (rituximab, cyclophosphamide, methotrexate)
- Seacross Pharmaceuticals (cyclophosphamide)
- Strides Pharma UK (azathioprine)
- Teva Pharma (mycophenolate mofetil)
- Tillomed Laboratories (azathioprine, mycophenolate mofetil)
- Zentiva (hydroxychloroquine)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS England Specialised Rheumatology Clinical Reference Group
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Bone Research Society
- British Skin Foundation
- Centre of Evidence-Based Dermatology, University of Nottingham
- Chronic Pain Policy Coalition
- Cochrane Heart, Stroke and Circulation
- Cochrane Kidney and Transplant Group
- Cochrane Musculoskeletal Group
- Cochrane Skin Group
- Dermatrust
- Genomics England
- Kidney Research UK
- MRC Clinical Trials Unit
- National Institute for Health Research
- Orthopaedic Research UK
- Pain Relief Foundation
- Thrombosis Research Institute
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 May 2026 | Invitation to participate |
| 23 February 2026 - 23 March 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 23 February 2026 | In progress. Scoping commenced. |
| 12 November 2025 | Topic selection |
| 03 November 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual